Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity

Launched by PFIZER · Nov 3, 2020

Keywords

ClinConnect Summary

This study is designed to look at the effect of two doses of PF 06882961 (120 milligram (mg) twice a day (BID) and 200 mg BID) on the levels of one dose of rosuvastatin 10 mg and one dose of midazolam 2 mg, in otherwise healthy, adult participants with obesity. Total duration of study from screening to the telephone visit will be approximately 17 weeks, of which up to 63 days will be inpatient. All subjects take (i) Rosuvastatin alone, Midazolam alone, PF 06882961 alone (120 mg BID), PF 06882961 (120 mg BID) + Rosuvastatin, PF 06882961 (120 mg BID) + Midazolam, PF 06882961 (200 mg BID) alon...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Body Mass Index (BMI) ≥ 30.0 kg/m2 and not more than 45.4 kg/m2 at Screening.
• • Stable body weight, defined as \<5 kg change (per participant report) for 90 days before Screening
• Exclusion Criteria:
• • Known prior participation in a trial involving PF-06882961.
• • Known intolerance or hypersensitivity to GLP-1R agonists.
• • Known hypersensitivity to rosuvastatin or midazolam.
• • Diagnosis of type 1 or type 2 diabetes mellitus or secondary forms of diabetes at screening. Note: prior diagnoses of gestational diabetes during pregnancy only are eligible if they meet the other eligibility criteria
• • Any lifetime history of a suicide attempt.
• • Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
• • Participation in a formal weight reduction program (eg, Weight Watchers) within 90 days prior to Screening.